Image pharmaphorum Editor Partner Content Partner Content AXON marks its spot…with more than an X AXON today launched a new brand visual identity to showcase its single-minded commitment to being ‘at the forefront of l R&D Importance of diversity in pharma and clinical trials “Diversity.” It’s a word that is very commonly thrown around right now, not just in pharma and healthcare but across all industries. Market Access How does rare disease prevalence impact drug pricing in Engl... In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discusses the role that disease rarity plays in reimbursement decisions among pa News Can synthetic control arms and real-world data offer a new w... Load more results
Partner Content Partner Content AXON marks its spot…with more than an X AXON today launched a new brand visual identity to showcase its single-minded commitment to being ‘at the forefront of l
R&D Importance of diversity in pharma and clinical trials “Diversity.” It’s a word that is very commonly thrown around right now, not just in pharma and healthcare but across all industries.
Market Access How does rare disease prevalence impact drug pricing in Engl... In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discusses the role that disease rarity plays in reimbursement decisions among pa
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
